This early-stage trial is testing whether adding a specific mix of gut bacteria (MB097) to a standard immunotherapy drug (pembrolizumab) can help patients with advanced melanoma whose cancer has stopped responding to similar treatments. The main goal is to see if this combination…
Phase: PHASE1 • Sponsor: Microbiotica Ltd • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC